-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KpE3JqHDwhqeoXQAGag/iNOjrV/T0KP2TE0+35uevS9VS0GOj6mSzXTh+xgJ5Njs 9UNVM/khgh8WGhjeBW1CNQ== 0001354457-10-000045.txt : 20100226 0001354457-10-000045.hdr.sgml : 20100226 20100226094506 ACCESSION NUMBER: 0001354457-10-000045 CONFORMED SUBMISSION TYPE: 25-NSE CONFIRMING COPY: PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20100226 DATE AS OF CHANGE: 20100226 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: VIA Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001003929 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330687976 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE SEC ACT: 1934 Act SEC FILE NUMBER: 000-27264 BUSINESS ADDRESS: STREET 1: 750 BATTERY STREET STREET 2: SUITE 330 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 415-283-2200 MAIL ADDRESS: STREET 1: 750 BATTERY STREET STREET 2: SUITE 330 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 FORMER COMPANY: FORMER CONFORMED NAME: CORAUTUS GENETICS INC DATE OF NAME CHANGE: 20030206 FORMER COMPANY: FORMER CONFORMED NAME: GENSTAR THERAPEUTICS CORP DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: UROGEN CORP DATE OF NAME CHANGE: 19960508 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NASDAQ Stock Market LLC CENTRAL INDEX KEY: 0001354457 IRS NUMBER: 521165937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25-NSE BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-978-4144 MAIL ADDRESS: STREET 1: 9600 BLACKWELL RD CITY: ROCKVILLE STATE: MD ZIP: 20850 25-NSE 1 primary_doc.xml X0203 0001354457 NASDAQ Stock Market LLC 0001003929 VIA Pharmaceuticals, Inc. 000-27264
750 Battery St. Suite 330 San Francisco CA CALIFORNIA 94111
404-526-6200 Common Stock 17 CFR 240.12d2-2(b) Amy Horton Associate General Counsel 2010-02-26 EX-99.25 2 viapdelistreason.txt Delisting Determination,The Nasdaq Stock Market, LLC, February 26, 2010, VIA Pharmaceuticals, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of VIA Pharmaceuticals, Inc. (the Company), effective at the opening of the trading session on March 8, 2010. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(b)(1). The Company was notified of the Staffs determination on July 15, 2009. Upon review of the information provided by the Company, the Panel issed a decision dated October 9, 2009, granting the Company continued listing pursuant to an exception through December 31, 2009, by which date the Company was required to regain compliance with Listing Rules 5550(b)(1), 5605(b)(1) and 5605(c)(2). However, the Company did not regain compliance by that date. On December 29, 2009, the Panel notified the Company that trading in the Companys securities would be suspended on January 4, 2010. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on February 12, 2010. -----END PRIVACY-ENHANCED MESSAGE-----